A recent study by Duke University researchers has identified key risk factors for Black men diagnosed with early-onset prostate cancer. Genetic variants and a family history of cancer are associated with an increased risk of developing the disease. The study's findings could help reduce racial disparities in prostate cancer outcomes.
Research emphasizes the importance of ethnically diverse prostate cancer genomics data and accessible genetic testing. Variations in genomic landscape of prostate cancer were observed in Chinese men compared to Western cohorts, with lower mutation rates in driver genes such as TP53 and PTEN.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Black and Hispanic men are underrepresented in prostate cancer clinical trials compared to their incidence rate. The representation of Black patients has remained consistently low over the past two decades.
A single drug compound attacks prostate cancer on several fronts by triggering immune cells to attack, helping them penetrate the tumor, and cutting off its ability to use testosterone as fuel. The study found that the drug activates anti-cancer T cells in a novel way and increases their ability to penetrate tumors.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A new treatment approach using surgery or radiation therapy has been shown to slow cancer progression in patients with solitary prostate cancer metastases. The study found that this approach, called metastasis-directed therapy (MDT), can delay the need for hormone-blocking treatments and improve survival rates.
A study found that top YouTube and TikTok videos on prostate cancer screening recommendations have low to moderate quality consumer health information. Black and Hispanic representation was underrepresented in most videos, and high-risk racial groups were not discussed adequately.
A novel radiopharmaceutical treatment targeting prostate-specific membrane antigen effectively shrinks prostate tumors in mice, with minimal impact on major organs. Researchers plan to launch a clinical trial for refractory prostate cancer patients in two years.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers developed a polygenic hazard score based on 290 genetic variants to predict genetic risk of lethal prostate cancer. The study analyzed nearly 591,000 men and found that the score adds considerably more information for individualized risk assessment, potentially benefiting high-risk men with accurate screening.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
The EXTEND trial found that combining metastasis-directed radiation therapy with intermittent hormone therapy improved progression-free survival in men with oligometastatic prostate cancer. The treatment also prolonged the time men could safely maintain normal testosterone levels, preserving their quality of life.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.
A phase III clinical trial confirms the safety and efficacy of a moderately shortened course of radiation therapy for men with high-risk prostate cancer. The study found no significant differences in survival rates, side effects, or recurrence between 5-week and 8-week radiation therapy.
A new analysis by UCLA Jonsson Comprehensive Cancer Center found that men with prostate cancer benefit from adding androgen deprivation therapy to radiation treatment. The study showed improved metastasis-free survival for patients receiving short-term ADT before or after radiation, especially in those receiving prostate-only RT.
A new study found that sexual side effects of cancer treatment are discussed less frequently with female patients, who are asked about their sexual health 1 in 10 times, compared to 9 in 10 men. The disparity is also observed in clinical trials nationwide.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
Researchers at Baylor College of Medicine discovered a novel approach to suppress the growth of therapy-resistant prostate cancer tumors. By enhancing GATA2 degradation, the study found marked suppression of tumor growth and castration resistance in animal models.
Scientists have identified two new epigenetic biomarkers that can predict the development of aggressive prostate cancer, enabling clinicians to develop more personalized treatment plans. The study used comprehensive molecular analysis of 185 biopsies from men with prostate cancer diagnosed between 1990 and 2000.
Researchers discovered that FOXA1, a cancer-causing gene, regulates alternative splicing in prostate cancer, influencing disease relapse and patient survival. The study identified specific splice variants linked to cancer recurrence, which could serve as markers for disease relapse and potential drug targets.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Researchers at UEA discovered that 'normal' prostate cells in men with prostate cancer have specific genetic changes that facilitate the growth and spread of cancer. The study suggests treating the whole prostate, not just affected areas, may be more effective.
African American men are twice as likely to have more aggressive disease compared to non-African American men. Genomic biomarker tests like the Decipher score can identify patients with higher-risk disease, enabling tailored treatment approaches.
A new study reveals that androgen receptor inhibitors can fundamentally rewire prostate tumors, making them more aggressive. The researchers found that most tumors remain fuel-dependent after treatment, but a small percentage convert to double-negative prostate cancer.
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A new study suggests that neoadjuvant novel hormonal therapy followed by prostatectomy can reduce the risk of recurrent and progressive cancer in high-risk prostate cancer patients. After treatment with NHAs, patients were more likely to have negative margins after surgery and fewer cases of biochemical recurrence.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
A study from the University of Gothenburg found that the number of surgeries performed by a urology surgeon has no effect on men's risk of developing postoperative urinary incontinence after prostate cancer surgery. The researchers analyzed data from over 4,600 men who underwent robot-assisted radical prostatectomy between 2017 and 2019.
A new study shows that PSMA PET/CT imaging can change treatment plans for nearly 50% of patients with prostate cancer recurrence after radical prostatectomy. The imaging technique detected disease in 46.9% of patients, leading to major changes in treatment plans, including recommendations for additional treatments.
Researchers have identified genetic signatures explaining ethnic differences in prostate cancer severity, particularly in African men. The study found a new prostate cancer taxonomy and cancer drivers that predict life-threatening cancers, providing a critical key to understanding the disease.
A large-scale study by the University of Exeter found that incorporating genetic risk into GP triage processes can improve referrals for those in need, while avoiding unnecessary invasive biopsy investigations for those at low risk. This approach has the potential to significantly impact prostate cancer diagnosis and treatment.
Annual PSA screening associated with reduced risk of prostate cancer-specific mortality among non-Hispanic Black men. The study suggests that annual screening may be particularly important for Black men, reducing their risk compared to less frequent screening.
Men with early prostate cancer are missing opportunities for detection because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence. Prostate cancer can be a silent or asymptomatic disease, particularly in its curable stages.
A new study found that over half of adult cancer survivors experience significant hearing problems after chemotherapy treatment. The researchers also discovered that platinum and taxane drugs, commonly used to treat the majority of cancers, are linked to high rates of hearing loss and tinnitus.
The Tango assay combines accumulation and a logical AND gate operation to identify prostate cancer biomarkers in blood samples. It achieves 91% accuracy in detecting prostate cancer in just 15 minutes, offering a non-invasive alternative to biopsies.
SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJul 20, 2022
Researchers at Umea University have discovered a new function in specific proteins involved in TGF-β signalling pathway, which affects how cancer cells grow and spread. This may lead to easier identification of men at risk of developing aggressive prostate cancer, enabling early treatment.
Researchers have found that high levels of iron can generate toxic free radicals, which damage lipids and ultimately lead to cell death. The team is exploring the use of compounds like JKE-1674 to induce ferroptosis in prostate cancer cells, making them more vulnerable to treatment.
A new study found that men at heightened genetic risk of prostate cancer who adopt healthy lifestyles may see a significant reduction in lethal disease risk. Maintaining a healthy weight, regular physical exercise, and not smoking were key factors associated with a reduced risk.
A study published in the Journal of Clinical Oncology found that biochemical failure is not a reliable surrogate endpoint for overall survival in patients with recurrent prostate cancer. The researchers recommend considering metastasis-free survival (MFS) as the best surrogate endpoint for overall survival in this population.
A Moffitt study shows that adaptive therapy using abiraterone improves patient outcomes and reduces care costs. The approach delays treatment withdrawal to prevent resistant cells from proliferating, leading to longer median time to progression and overall survival.
Researchers have devised a way to deliver carbon monoxide to the body using stable foams that can be delivered to the digestive tract. The foams reduced inflammation of the colon and helped reverse acute liver failure in mice, offering a potential alternative to immunosuppressive treatments.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.
Current guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to consider information from PSMA PET imaging. PSMA PET is effective in identifying recurrences partially or fully outside the clinical target volume, suggesting its value for therapy planning.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
A new Loma Linda University study associates high dairy milk intake with a significantly increased risk of prostate cancer. Researchers found no association between non-dairy calcium and prostate cancer risk, suggesting substances other than calcium contribute to the increased risk.
Experts advise against routine prostate cancer tests for asymptomatic men due to the test's limited ability to prevent deaths and potential for overdiagnosis. Instead, they recommend using a 'risk checker' tool to explore options with a doctor, emphasizing the need for evidence-based guidance on PSA testing.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new subtype of prostate cancer that accounts for 30% of all cases. This stem cell-like subtype, characterized by specific gene expression patterns, is the second most prevalent group after androgen-sensitive type.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
A combination of hormone therapy and pelvic lymph node radiation treatment significantly improved survival rates among patients with postoperative prostate cancer, extending their lives by nearly five years. This study published in The Lancet found that nearly 90% of clinical trial patients remained free from progression for five years.
Research found that men taking abiraterone or enzalutamide plus hormone therapy had a higher risk of metabolic and cardiovascular issues than those undergoing hormone therapy alone. This increased risk was observed in patients with Medicare health insurance, who were significantly older than those in clinical trials.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
Researchers developed a biosensor using nanostructured and nanoporous surfaces to detect biomarkers in clinical samples, overcoming technical challenges of small sample amounts. The new technology can provide quick and accurate diagnoses for diseases like prostate cancer without needing dilution or preprocessing steps.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
Research suggests that PSA screening can prevent a significant number of prostate cancer deaths, with lower numbers than previously estimated. The study's findings support the benefits of PSA screening, especially for young healthy men and Black men, who have historically been underrepresented in clinical trials.
Researchers identified genetic patterns in brain metastatic prostate cancer cells, revealing potential targets for PARP inhibitor therapy. This study contributes to precision medicine by tailoring treatment to individual patient profiles.
A large population study found that smoking increases the risk of dying from prostate cancer, regardless of tumor stage, and is associated with a poorer prognosis. Smokers have a lower risk of developing prostate cancer but are more likely to be diagnosed at an advanced stage.